Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LP-118 · 1 trial · 1 indication
Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.
Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.
| Arm | Type | Description |
|---|---|---|
| Combination of LP-118, ponatinib, dexamethasone, blinatumomab and methotrexate | EXPERIMENTAL | LP-118 will be given as tablets of 10mg or 100mg during the induction II course only in combination with ponatinib, dexamethasone, methotrexate and blinatumomab. . Ponatinib, dexamethasone and methotrexate dosing will remain fixed, whereas LP-118 dosing will be dependent on the dose level to which a participant is assigned. |
| Name | Type | Description |
|---|---|---|
| LP-118 | DRUG | s LP-118 dosing will be dependent on the dose level to which a participant is assigned: * 50mg PO * 100mg PO * 200mg PO * 300mg PO |
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent. * Age ≥ 18 years at the time of consent. * ECOG Performance Status (PS) ≤ 2. * Histological or cytological confirmation of newly diagnosed CD19-positive Philadelphia-chromosome/BCR::ABL1-positive A...
LP-118 is an investigational small molecule being studied for the treatment of Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adults. It is currently in Phase 1 clinical development.
LP-118 is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol RNA.
LP-118 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. It is being studied in a Phase 1 trial for adults with newly diagnosed Ph+ ALL.
LP-118 is being studied in a Phase 1 clinical trial with the identifier NCT07614022. The trial is evaluating LP-118 in combination with ponatinib, dexamethasone, and blinatumomab in adults with newly diagnosed, BCR::ABL1-positive acute lymphoblastic leukemia. The trial is not yet recruiting and has a planned enrollment of 26 participants.
The Phase 1 clinical trial of LP-118 is not randomized and not double-blinded. It is an uncontrolled study, meaning there is no control group. The trial is open to all sexes and participants must be at least 18 years old.